Molecular Partners AG logo

Molecular Partners AG

SIX:MOLN.SW

Overview | Financials
Company Name Molecular Partners AG
Symbol MOLN.SW
Currency CHF
Price 9
Market Cap 298,638,900
Dividend Yield 0%
52-week-range 3.04 - 9.5
Industry Biotechnology
Sector Healthcare
CEO Dr. Patrick Amstutz Ph.D.
Website https://www.molecularpartners.com

An error occurred while fetching data.

About Molecular Partners AG

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular

Related Stocks

Relief Therapeutics Holding AG logo

Relief Therapeutics Holding AG

RLF.SW

1.11 CHF

SHL Telemedicine Ltd. logo

SHL Telemedicine Ltd.

SHLTN.SW

8.9 CHF

IVF Hartmann Holding AG logo

IVF Hartmann Holding AG

VBSN.SW

129 CHF

Ascom Holding AG logo

Ascom Holding AG

ASCN.SW

7.69 CHF

Evolva Holding SA logo

Evolva Holding SA

EVE.SW

0.97 CHF

Kuros Biosciences AG logo

Kuros Biosciences AG

KURN.SW

11.4 CHF

Basilea Pharmaceutica AG logo

Basilea Pharmaceutica AG

BSLN.SW

40.55 CHF

Newron Pharmaceuticals S.p.A. logo

Newron Pharmaceuticals S.p.A.

NWRN.SW

10.72 CHF

Financials

Numbers are in millions USD

Numbers are in millions USD